| abstract |
The present invention relates to 8-aryl-quinoline derivatives, in particular salts of 8-aryl-quinoline-substituted aryl-substituted 8-aryl-quinoline derivatives, which inhibit the activity of the 4-phosphodiesterase enzyme. In the formula (I), the 8-arylquinoline derivatives of the present invention are each S, H, S2 and S3; R1 is hydrogen, hydroxy, halogen, carbonyl, alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl, cyano, heterocycloalkyl, amino, alkylamino, dialkylamino, alkyloxyalkyl, (aryl) - aminocarbonyl group, (heteroaryl) aminocarbonyl group, arylamino-SOn group, heteroaryl-aminoSOn group, alkylamino-SOn group, dialkylaminocarbonyl group, alkylSOn-amino group, alkyl- A SOn group, a di (alkylamino) -C (CN) -O (alkyl) group or an (alkyl) -SOn (alkyl) group, with the proviso that the groups may be optionally substituted with 1 to 5 independent substituents; A is CH; R2 and R3 are independently selected from the group consisting of aryl, heteroaryl, hydrogen, halogen, cyano, alkyl, heterocycloalkyl, alkoxy, carbonyl, carbamoyl, (alkyl) -SO (alkyl), dialkylaminocarbamoyl, and aminoalkyl; acyl, with the proviso that the groups may be optionally substituted with 1 to 5 substituents which may themselves be substituted; R 4 is aryl, alkyl, heteroaryl, cyano, carbonyl, carbamoyl, (alkyl) -SO 2 - (alkyl) -; a dialkylaminocarbonyl group or an aminoacylalkyl group, with the proviso that the groups may be optionally substituted with 1 to 5 substituents; and n is 0, 1 or 2. The invention also encompasses pharmaceutical compositions containing the compounds. SHE |